The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2025
Asked but not received: postpartum contraception access in opioid-using pregnant patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Root Emily R, Farabee Elizabeth A, Byrket Katherine B, Jatczak Justin M, Franklin Tanya, Kline Jessica, Tonismae Tiffany, Miller Edward E
Аннотация
PURPOSE: To identify differences between desired and received postpartum contraception in opioid-using pregnant patients.
MATERIALS AND METHODS: This single-centre retrospective study included pregnant patients who reported current opioid use, with a positive urine drug screen (UDS) for opioids, and a documented contraceptive plan in the medical record who delivered between December 1, 2016, and December 31, 2020. Patients who delivered outside the sponsoring institution and those taking medications for opioid use disorder (MOUD) or hospital-administered opioids were excluded. Descriptive statistics were performed including counts, percentages, and means.
RESULTS: A total of 101 patients met the criteria for inclusion. Over two-thirds of patients did not receive their desired form of contraception at the time of hospital discharge. Long-acting reversible contraception (LARC) was the most preferred form of contraception at the time of admission. Depot medroxyprogesterone acetate (DMPA) was the most common contraceptive received at the time of hospital discharge, with around one-third of patients receiving DMPA. Only 25 patients (24.8%) presented for a postpartum follow-up appointment. Of the women who did not receive their desired form of contraception at the time of discharge, 19 (27.9%) were pregnant again within two years.
CONCLUSIONS: Increased focus is needed on the prevention of unintended pregnancies in opioid-using patients, including policies to increase access to contraception, including LARCs.
MATERIALS AND METHODS: This single-centre retrospective study included pregnant patients who reported current opioid use, with a positive urine drug screen (UDS) for opioids, and a documented contraceptive plan in the medical record who delivered between December 1, 2016, and December 31, 2020. Patients who delivered outside the sponsoring institution and those taking medications for opioid use disorder (MOUD) or hospital-administered opioids were excluded. Descriptive statistics were performed including counts, percentages, and means.
RESULTS: A total of 101 patients met the criteria for inclusion. Over two-thirds of patients did not receive their desired form of contraception at the time of hospital discharge. Long-acting reversible contraception (LARC) was the most preferred form of contraception at the time of admission. Depot medroxyprogesterone acetate (DMPA) was the most common contraceptive received at the time of hospital discharge, with around one-third of patients receiving DMPA. Only 25 patients (24.8%) presented for a postpartum follow-up appointment. Of the women who did not receive their desired form of contraception at the time of discharge, 19 (27.9%) were pregnant again within two years.
CONCLUSIONS: Increased focus is needed on the prevention of unintended pregnancies in opioid-using patients, including policies to increase access to contraception, including LARCs.